vTv Therapeutics (VTVT) Projected to Post Earnings on Thursday

vTv Therapeutics (NASDAQ:VTVT) is projected to announce its quarterly earnings results before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.90) per share for the quarter.

vTv Therapeutics (NASDAQ:VTVT) last released its earnings results on Thursday, March 20th. The biotechnology company reported ($0.55) earnings per share for the quarter, topping the consensus estimate of ($0.87) by $0.32. The business had revenue of $0.02 million for the quarter.

vTv Therapeutics Trading Down 0.2 %

Shares of VTVT opened at $21.68 on Wednesday. The firm has a market capitalization of $69.14 million, a P/E ratio of -4.78 and a beta of 0.77. vTv Therapeutics has a 12-month low of $12.12 and a 12-month high of $29.01. The firm has a fifty day moving average price of $18.38 and a 200-day moving average price of $16.57.

Wall Street Analyst Weigh In

A number of brokerages have commented on VTVT. StockNews.com began coverage on shares of vTv Therapeutics in a research note on Wednesday, April 16th. They issued a “sell” rating on the stock. HC Wainwright assumed coverage on vTv Therapeutics in a research note on Wednesday, April 9th. They issued a “buy” rating and a $36.00 price objective on the stock.

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.